Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN) announces it has acquired Lung Therapeutics, Inc. (“Lung Tx”), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron’s Series X non-voting convertible preferred stock (the “Series X preferred stock”) and warrants to purchase shares of Aileron’s common stock in a private placement to a group of accredited investors led by Bios Partners (“Bios”), and including Nantahala Capital, as well as additional undisclosed investors.
Read the full article: Aileron Therapeutics Announces Acquisition of Lung Therapeutics //
Source: https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-acquisition-of-lung-therapeutics-301973050.html